[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-lung-cancer-detection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-lung-cancer-detection":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636983","champ-lung-cancer-screening-program-100636983",false,"NCT07572773","CHAMP Lung Cancer Screening Program","CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program","CHAMP","Inclusion Criteria:\n\n* aged 50-77\n* smoking pack-year history of ≥ 20 years\n* current smoker or quit smoking 15 or less years ago\n* ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* self-report of lung cancer screening in the last 12 months\n* psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","ALL","50 Years","77 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care.\n\nEligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.",[28,29],"Lung Cancer","Early Lung Cancer Detection",[31,32,33,34,35],"lung cancer","early lung cancer detection","lung cancer screening","community pharmacy intervention","pharmacy cancer screening","RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":37,"type":40},{"date":43,"type":22},"2028-06",{"name":45,"class":46},"Jill Kolesar","OTHER",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100620522","liquid-biopsy-based-pre-screening-to-streamline-ldct-lung-cancer-screening-in-high-risk-individuals-100620522","NCT07358715","Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals","A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals","Inclusion Criteria\n\nHigh-Risk Individuals (n = 100)\n\n* No prior history of lung cancer\n* Meets one of the following high-risk definitions:\n\n  * Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR\n  * Never-smoker aged 55-75 years with a first-degree family history of lung cancer\n* Able and willing to provide written informed consent\n\nEarly-Stage Lung Cancer Patients (n = 20)\n\n* Aged ≥21 years\n* Histologically or clinically confirmed stage I-II lung cancer\n* Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer)\n* Able and willing to provide written informed consent\n\nAdvanced-Stage Lung Cancer Patients (n = 20)\n\n* Aged ≥21 years\n* Histologically or clinically confirmed stage III-IV lung cancer\n* Treatment-naïve (no prior systemic or local therapy for lung cancer)\n* Able and willing to provide written informed consent\n\nExclusion Criteria\n\nApplicable to All Participants\n\n* Pregnant or breastfeeding women\n* Inability or unwillingness to comply with study procedures\n\nHigh-Risk Individuals Only\n\n* Known allergy or contraindication to CT contrast agents\n* Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment\n\nLung Cancer Cohorts Only\n\n• Receipt of any prior cancer-directed treatment for lung cancer",true,"21 Years","75 Years",{"count":59,"type":22},140,[25],"This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.",[28,63,29,64,65],"Lung Neoplasms","Cancer Screening","High-Risk Populations",[67,68,69,70,71,72,73,74,75,76,77],"Liquid biopsy","DNA methylation","Exosomes","Blood-based screening","Low-dose CT","LDCT","Lung cancer screening","Early cancer detection","High-risk individuals","Never-smokers","Multimodal assay","2026-01-13",{"date":80,"type":40},"2026-01-22",{"date":82,"type":40},"2024-11-01",{"date":84,"type":22},"2028-12-31",{"name":86,"class":46},"National University Hospital, Singapore",1]